Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

7

Other

1

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclooxygenase-1

1

Cyclooxygenase-2

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

8

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

7

2012

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

penetration of radioactive iodine into the thyroid gland

7

Postoperative pain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

7

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Novartis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

9

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

9

FDA UNII

9

EPA CompTox

8

PUBCHEM

8

ECHA (EC/EINECS)

6

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

1

SENSORY ORGANS

1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ALL OTHER THERAPEUTIC PRODUCTS

1

COUGH AND COLD PREPARATIONS

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ALL OTHER THERAPEUTIC PRODUCTS

1

EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS

1

OTHER OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antidotes

1

Expectorants

1

Other ophthalmologicals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

6

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

IODIDE ION

09G4I6V86Q

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

4-ETHYLANILINE

MHX72W1ZQV

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

ROBENACOXIB

Z588009C7C

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2012

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Cyclooxygenase-2

Cyclooxygenase-1

Conditions:

Postoperative pain

Robenacoxib (trade name Onsior) is a non-steroidal anti-inflammatory drug (NSAID) used in veterinary medicine for the relief of pain and inflammation in cats and dogs. In an inflammation model in cats, Robenacoxib had analgesic, anti-inflammatory and...

antipyretic actions with a rapid onset of action (0.5 h). In an in vitro whole blood assay in cats, Robenacoxib demonstrated selective COX-2 inhibition. After oral administration of robenacoxib tablets at 1 mg/kg without food, peak blood concentrations are attained rapidly with a median Tmax of 0.5 h, a mean Cmax of 1159 ng/ml and a mean AUC of 1337 ng*h/ml. Robenacoxib persists longer in the inflammatory exudate of a tissue cage model than in blood. The median Robenacoxib elimination half-life in exudate was about 27 hours versus 2.5 hours for blood. Robenacoxib is extensively metabolized by the liver in cats. The systemic exposure of lactam metabolite is about 25% of Robenacoxib exposure following oral administration to fed cats. Further, the systemic exposure to lactam appears to be two-fold greater in fed cats than fasted cats. Apart from one lactam metabolite, the identity of other metabolites is not known in cats.

Iodine, atomic

5D3DB66WM3

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

POTASSIUM PHOSPHIDE

2F09226A2C

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

ETHYLENEDIAMINE DIHYDRIODIDE

721M52NQ5L

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

Potassium iodide

1C4QK22F9J

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

Sodium iodide

F5WR8N145C

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

HYDROGEN IODIDE

694C0EFT9Q

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1